Menu Search
Equities

Galapagos NV

GXEA:STU

Galapagos NV

Actions
  • Price (EUR)23.40
  • Today's Change-1.60 / -6.40%
  • Shares traded0.00
  • 1 Year change-27.33%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.

  • Revenue in USD (TTM)318.02m
  • Net income in USD-63.48m
  • Incorporated1999
  • Employees683.00
  • Location
    Galapagos NVGeneraal De Wittelaan L11 A3MALINES (MECHELEN) 2800BelgiumBEL
  • Phone+32 15342900
  • Fax+32 15342901
  • Websitehttps://www.glpg.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.